Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential

Fig. 1

Anti-CD47 nanobody discovery. a SDS-PAGE of purified CD-47 ectodomain (ECD) antigen. Lane 1 was loaded with protein ladder; Lane 2 showed purified human CD47 (ECD)-Fc antigen. The samples were separated by using 10% gradient PAGE gels and stained with Coomassie blue. The experiment was performed in triplicate and one representative experiment was shown. b The enrichment fold for phage particles in wells coated with antigen versus wells without antigen was detected after each round of panning. The experiment was performed once. c The blocked nanobody was selected by FACS. The Nb1-IgG4 was identified that could block the interaction between human CD47 and SIRPĪ±. The experiment was performed in triplicate and one representative experiment was shown

Back to article page